Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > CPH's Hospital Products: Deal with Verity -> Revenue Growth

<< Previous

Bullboard Posts

Next >>

Comment by stockfyon Mar 04, 2021 2:47am

65 Views

Post# 32712539

RE:CPH's Hospital Products: Deal with Verity -> Revenue Growth

Facts here about the recent deal with Verity.

stockfy wrote:

Good news. CPH just announced a deal for its hospital products that will contribute to revenue growth in the next months:

https://cipher.investorroom.com/2021-02-10-Cipher-Pharmaceuticals-Enters-into-Co-Promotion-Agreement-with-Verity-Pharmaceuticals-Inc

"Under the terms of the Agreement, Verity will be responsible for the co-promotion of all hospital products inclusive of all costs and expenses associated with those products. Verity will be compensated by receiving a tiered percentage of the net margin of the products."

Meanwhile, debt-free and profitable CPH is working on additional growth opportunities, according to the latest CC:

"The COVID-19 pandemic continued to impact the economy during the third quarter of 2020. Cipher is navigating through this environment while executing on business improvements and cost reductions. Cipher demonstrated strong profitability during the third quarter and sequential growth in revenue, despite market conditions that have not fully normalized. Our focus continues to be on driving profitability, strengthening the balance sheet and looking for the right opportunities for growth. "